# EARLY STOPPING OF CLINICAL TRIALS

> **NIH NIH R01** · DANA-FARBER CANCER INST · 1989 · $69,079

## Abstract

The major purpose of this research is to formulate the best way
that sequential designs can be implemented in clinical trials when
the major endpoint of interest is length of survival.  We propose
to develop a computer algorithm which will find the sequential
design which minimizes either total accrual or time to
termination of a study, while still preserving the overall level of
significance and power to detect a clinically significant
difference.

We also propose to develop methodology for deriving the exact
sequential distribution of nonparametric test statistics, computed
after groups of observations.  This will be used for deriving exact
group sequential tests with studies that have moderate sample
size.

Finally, we will investigate the bias of fixed sample inference
following a group sequential test and indicate how to adjust the
inference to minimize the bias.

## Key facts

- **NIH application ID:** 3174017
- **Project number:** 5R01CA036446-06
- **Recipient organization:** DANA-FARBER CANCER INST
- **SAM.gov UEI:** DPMGH9MG1X67
- **Principal Investigator:** ANASTASIOS A TSIATIS
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $69,079
- **Award type:** 5
- **Project period:** 1983-08-01 → 1989-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3174017

## Citation

> US National Institutes of Health, RePORTER application 3174017, EARLY STOPPING OF CLINICAL TRIALS (5R01CA036446-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3174017. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*